-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 11, 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

When considering monotherapy with second-generation BTKi, what factors do you consider when choosing between available agents?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

CLL image | Image Credit: © Momius-stock.adobe.com

Acalabrutinib May Weaken Rituximab’s Efficacy in CLL

ByMaggie L. Shaw

July 31st 2026

Kerry Rogers, MD | Image Credit: © The James

Why CAR T Isn’t a Simple “Cure” for CLL: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

July 29th 2026

CLL | Image Credit: © momius-stock.adobe.com

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%

ByMaggie L. Shaw

July 25th 2026

Leukemiaonwoodenblocks| Image Credit: © bo-stock.adobe.com

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL

ByMaggie L. Shaw

July 22nd 2026

Kerry Rogers, MD, Talks BTK Inhibitor Sequencing, Cost, Access in CLL

ByMaggie L. Shaw,Kerry Rogers, MD

July 15th 2026

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

FDA Panel Backs 6 Peptides for Compounding

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

Pediatric Chronic Skin Disorders Linked to Poorer Mental Health